RIAMIDE 5mg/5ml Price

Overview

Welcome to Dwaey, specifically on RIAMIDE 5mg/5ml Syrup page.
This medicine contains an important and useful components, as it consists of Metoclopramide HCl.
RIAMIDE 5mg/5ml is available in the market in concentration 5mg/5ml and in the form of Syrup.

RIYADH PHARMA (MEDICAL AND COSMETIC PRODUCTS COMPANY LTD.) is the producer of RIAMIDE 5mg/5ml and it is imported from SAUDI ARABIA, The most popular alternatives of RIAMIDE 5mg/5ml are listed downward .

Mode Of Action

Metoclopramide enhances the motility of the upper GI tract and increases gastric emptying without affecting gastric, biliary or pancreatic secretions. It increases duodenal peristalsis which decreases intestinal transit time, and increases lower oesophageal sphincter tone. It is also a potent central dopamine-receptor antagonist and may also have serotonin-receptor (5-HT3) antagonist properties.

Indication

• Gastro-oesophageal reflux disease
• Diabetic gastric stasis
• Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy
• Postoperative nausea and vomiting

Precaution

Patients w/ underlying neurological conditions, cardiac conduction disturbances, uncorrected electrolyte imbalance, bradycardia. Children, elderly. Renal or hepatic impairment, porphyria, epilepsy, Parkinson's disease, history of depression. Ability to drive or operate machineries may be impaired. Pregnancy and lactation. Monitor patients on prolonged therapy. Increased risk of tardive dyskinesia in patients on prolonged or high-dose treatment. Lactation: Drug crosses into breast milk; use caution; concern may be warranted according to American Academy of Pediatrics

Side Effects

• >10% Extrapyramidal symptoms (dystonic reactions in 25% of young adults 18-30 years old) 1-10% Fatigue (2-10%)
• Restlessness (10%)
• Sedation (10%)
• Headache (4-5%)
• Dizziness (1-4%)
• Somnolence (2-3%) Frequency Not Defined Diarrhea
• Nausea
• Galactorrhea
• Gynecomastia
• Impotence
• Menstrual disorders
• Neuroleptic malignant syndrome
• Hematologic abnormalities Potentially Fatal: Neuroleptic malignant syndrome; cardiac conduction disorders may occur with IV dosage form.

Contra indication

GI haemorrhage, mechanical obstruction or GI perforation; confirmed or suspected pheochromocytoma; history of neuroleptic or metoclopramide-induced tardive dyskinesia; epilepsy, Parkinson's disease; history of methaemoglobinaemia w/ metoclopramide or of NADH cytochrome-b5 deficiency. Concomitant use w/ levodopa or dopaminergic agonists.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.